Fractional-dose yellow fever vaccination: an expert review

Anna H E Roukens, Leo G Visser, Anna H E Roukens, Leo G Visser

Abstract

Rationale for review: The global yellow fever vaccine supply is insufficient to provide full-dose vaccination to millions threatened by outbreaks. Given the excess of live-attenuated 17D yellow fever virus in the current single dose vials, dose sparing would increase available vaccine doses manifold. Fractional-dose yellow fever vaccination is now accepted as an emergency solution, as short-term protection has been confirmed in an outbreak situation in the Democratic Republic of Congo, but broader application of this dose-sparing strategy is still not recommended. In this review, important knowledge gaps that hamper this application such as long-term protection after fractional-dose vaccination, safety, comparability across different genetic backgrounds and different World Health Organization-licensed yellow fever vaccines and immunogenicity in infants are addressed.

Main findings: Recently, published results on long-term protection after fractional-dose vaccination in healthy young volunteers indicate that if a person mounts a protective response shortly after vaccination, the protective response will persist for 10 years and possibly longer. It also appears that fractional-dose vaccination does not elicit more serious adverse events than standard dose vaccination. Short-term immunogenicity studies are currently underway in specific populations (infants, human immunodeficiency virus (HIV)-infected persons and healthy adults living in Uganda and Kenya), of which the results will become available in 2021-22.

Conclusions: Available results on long-lasting immunogenicity of fractional-dose yellow fever vaccination are encouraging, although confirmation is required in larger populations including young children living in yellow fever endemic areas.

Keywords: Yellow fever; fractional-dose vaccination; immunogenicity; knowledge gaps; pratical implications; safety.

© International Society of Travel Medicine 2019. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

References

    1. World Health Organization. Weekly epidemiological record. Eliminate Yellow fever Epidemics (EYE): a global strategy, 2017–2026. 2017; 16:193–204.
    1. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013; 89:434–444.
    1. World Health Organization . Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response. WHO Secretariat Information Paper. Geneva: World Health Organization; 20 July 2016. =1 (10 February 2019, date last accessed).
    1. Roukens AH, Vossen AC, Bredenbeek PJet al. . Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 2008; 3: e1993.
    1. Siegrist CA. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, and Edwards KM (eds). Plotkin’s vaccines, 7th edn. Philadelphia: Elsevier, 2018, p. 150.
    1. Martins RM, Maia M de L, Farias RHet al. . 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 2013; 9:879–888.
    1. Ahuka-Mundeke S, Casey RM, Harris JBet al. . Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med 2018.
    1. Nzolo D, Engo Biongo A, Kuemmerle Aet al. . Safety profile of fractional dosing of the 17DD yellow fever vaccine among males and females: experience of a community-based pharmacovigilance in Kinshasa, DR Congo. Vaccine 2018; 36:6170–6182.
    1. Vannice K, Wilder-Smith A, Hombach J. Fractional-dose yellow fever vaccination—advancing the evidence base. N Engl J Med 2018; 379:603–605.
    1. de Menezes Martins R, Maia MLS, de Lima SMBet al. . Collaborative Group for Studies on duration of immunity from yellow fever vaccine. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine 2018; 36:4112–4117.
    1. Roukens AHE, van Halem K, de Visser AWet al. . Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med 2018; 169:761–765.
    1. Gavi, the Vaccine Alliance . Yellow fever supply and procurement roadmap, UPDATE 20th March 2017. (10 February 2019, date last accessed).
    1. World Health Organization . WHO position on the use of fractional doses—June 2017, addendum to vaccines and vaccination against yellow fever WHO: position paper—June 2013. Vaccine 2017; 35:5751–5752.
    1. WHO Secretariat information paper . Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. (10 February 2019, date last accessed)
    1. Gubler DJ. Pandemic yellow fever: a potential threat to global health via travelers. J Travel Med 2018; 25:tay097.
    1. Teitelbaum P, Bui YG, Libman Met al. . Fractional dosing of yellow fever vaccine during shortages: perspective from Canada. J Travel Med 2018; 25.
    1. Roukens AH, Vossen AC, van Dissel, JT. et al. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009; 27:2408–2409.
    1. WHO . Short-term Research Priorities for Dose-sparing of Yellow Fever Vaccine. (10 February 2019, date last accessed).
    1. Monath TP, Fowler E, Johnson CTet al. . An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011; 364:1326–1333.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe